Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Annexon announces EMA selection of vonaprument for PDC

Summary by Pharmaceutical Business Review
Vonaprument, formerly known as ANX007, is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. It has secured Priority The post Annexon announces EMA selection of vonaprument for PDC pilot participation appeared first on Pharmaceutical Business review.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Pharmaceutical Business reviewPharmaceutical Business review

Annexon announces EMA selection of vonaprument for PDC

Vonaprument, formerly known as ANX007, is a first-in-kind, non-pegylated antigen-binding fragment (Fab) designed to block C1q locally in the eye with an intravitreal formulation. It has secured Priority The post Annexon announces EMA selection of vonaprument for PDC pilot participation appeared first on Pharmaceutical Business review.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pharmaceutical Business review broke the news in on Monday, August 11, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal